Added to YB: 2026-09-21
Pitch date: 2026-09-17
RMD [bullish]
ResMed Inc.
-1.41%
current return
Author Info
Goldman Won't Cover This shares independent deep research on small and mid-cap compounders that institutional money ignores. Sign up for the newsletter.
Company Info
ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally.
Market Cap
$32.7B
Pitch Price
$228.21
Price Target
N/A
Dividend
1.16%
EV/EBITDA
14.92
P/E
21.90
EV/Sales
5.67
Sector
Health Care Equipment and Supplies
Category
value
ResMed - Quality Healthcare on Sale (or is it a Value Trap?)
RMD: ResMed offers favorable risk/reward at 18.9x forward earnings versus a 38.58x ten-year average, with a 5.01% FCF yield and net buybacks near 3% annually. The market’s GLP-1 fear looks premature: guidelines do not treat the drugs as PAP replacements, and management says GLP-1 patients order 5-6% more supplies. The reverse DCF requires only ~3.5% underlying growth versus 5-7% FY2027 guidance, though AD109’s February 2027 FDA decision is the clearest unresolved threat.
Read full article (18 min)